Drug General Information (ID: DDI0MWHN7B)
Drug Name			Halofantrine		Drug Info		Lumefantrine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antimalarial Agents				Antimalarial Agents
Structure

Mechanism of Halofantrine-Lumefantrine Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Halofantrine				Lumefantrine
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Halofantrine and Lumefantrine

Recommended Action
Management		Halofantrine and lumefantrine should not be administered within one month of each other due to their long elimination half-lives (6 to 10 days for halofantrine and 3 to 6 days for lumefantrine).

References
1	Giao PT, de Vries PJ "Pharmacokinetic interactions of antimalarial agents." Clin Pharmacokinet 40 (2001): 343-73. [PMID: 11432537]
2	Product Information. Coartem (artemether-lumefantrine). Novartis Pharmaceuticals, East Hanover, NJ.
3	Product Information. Halfan (halofantrine). GlaxoSmithKline, Philadelphia, PA.